Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 144

Sort by

Sort Order Select

Journal Articles

Evolution of the Evidence for the Management of COVID-19 in Hematologic Malignancies: A Systematic Literature Review of Remdesivir

Essy Mozaffari, Michele Bartoletti, Jakob J. Malin, Yohei Doi, Paul Loubet, Christina G. Rivera, Garyfallia Poulakou, Aaditya Rawal, Emily Kaiser, Maria Vutcovici Nicolae, Elvira Schmidt, Thomas F. Oppelt, Mel Chiang, Carmelo Carlo-Stella, Paul E. Sax, Andre C. Kalil

Blood (2024) 144 (Supplement 1): 7750.

https://doi.org/10.1182/blood-2024-200253

Published: 2024

Journal Articles

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

Blood (2024) 144 (Supplement 1): 3123.

https://doi.org/10.1182/blood-2024-205544

Published: 2024

Journal Articles

A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna

Matin Salehi, Maria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi Di Bergamo, Federico Jauk, Gabriela Forestieri, Simone Bocchetta, Deborah Piffaretti, Riccardo Moia, Vanessa Cristaldi, Martina Di Trani, Georgia Alice Galimberti, Katia Pini, Valeria Spina, Claudia Giordano, Adalgisa Condoluci, Salvatore Annunziata, Fabrizio Bergesio, Renzo Boldorini, Eugenio Borsatti, Pietro Bulian, Stephane Chauvie, Marco Cuzzocrea, Bernhard Gerber, Michal Kurlapski, Luigi Maria Larocca, Andrea Rinaldi, Marcello Rodari, Grzegorz Romanowicz, Gian Mauro Sacchetti, Anastasios Stathis, Georg Stüssi, Ilaria Zangrilli, Eleonora Calabretta, Francesco Corrado, Antonello Pinto, Luca Mazzucchelli, Valter Gattei, Jan Maciej Zaucha, Armando Santoro, Stefan Hohaus, Franco Cavalli, Emanuele Zucca, Gianluca Gaidano, Carmelo Carlo-Stella, Alexandar Tzankov, Luca Ceriani, Davide Rossi

Blood (2024) 144 (Supplement 1): 854.

https://doi.org/10.1182/blood-2024-207234

Published: 2024

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Blood (2024) 144 (Supplement 1): 990.

https://doi.org/10.1182/blood-2024-200096

Published: 2024

Journal Articles

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Blood (2024) 144 (Supplement 1): 1631.

https://doi.org/10.1182/blood-2024-200018

Published: 2024

Journal Articles

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Blood (2024) 144 (Supplement 1): 644.

https://doi.org/10.1182/blood-2024-201406

Published: 2024

Journal Articles

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2024) 144 (Supplement 1): 865.

https://doi.org/10.1182/blood-2024-194333

Published: 2024

Journal Articles

Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Emmanuel Bachy, Peter Trask, Franck Morschhauser, Paolo Corradini, Shang-Ju Wu, Nancy L. Bartlett, Estefania Mulvihill, Fabiola Bene Tchaleu, Linda Lundberg, Carmelo Carlo-Stella

Blood (2024) 144 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2024-194337

Published: 2024

Journal Articles

Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy

Cristina Zucchinetti, Chiara Signori, Martina di Trani, Maria Cristina Pirosa, Alessio Bruscaggin, Koorosh Korfi, Alessia Bottos, Eleonora Calabretta, Francesco Corrado, Davide Rossi, Carmelo Carlo-Stella

Blood (2024) 144 (Supplement 1): 4356.

https://doi.org/10.1182/blood-2024-207596

Published: 2024

Journal Articles

Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma

Maria Cristina Pirosa, Matin Salehi, Alessio Bruscaggin, Lodovico Terzi Di Bergamo, Federico Jauk, Gabriela Forestieri, Simone Bocchetta, Deborah Piffaretti, Riccardo Moia, Vanessa Cristaldi, Martina di Trani, Georgia Alice Galimberti, Katia Pini, Valeria Spina, Claudia Giordano, Adalgisa Condoluci, Salvatore Annunziata, Fabrizio Bergesio, Renzo Boldorini, Eugenio Borsatti, Pietro Bulian, Stephane Chauvie, Marco Cuzzocrea, Bernhard Gerber, Michal Kurlapski, Luigi Maria Larocca, Andrea Rinaldi, Marcello Rodari, Grzegorz Romanowicz, Gian Mauro Sacchetti, Anastasios Stathis, Georg Stüssi, Ilaria Zangrilli, Eleonora Calabretta, Francesco Corrado, Antonello Pinto, Luca Mazzucchelli, Valter Gattei, Jan Maciej Zaucha, Armando Santoro, Stefan Hohaus, Franco Cavalli, Emanuele Zucca, Gianluca Gaidano, Carmelo Carlo-Stella, Alexandar Tzankov, Luca Ceriani, Davide Rossi

Blood (2024) 144 (Supplement 1): 2960.

https://doi.org/10.1182/blood-2024-208175

Published: 2024

Journal Articles

Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience

Filippo Bagnoli, Jacopo Calabrese De Feo, Francesca Livia Letizia Ricci, Jacopo Mariotti, Barbara Sarina, Monica Balzarotti, Daniela Taurino, Daniele Mannina, Chiara De Philippis, Daoud Rahal, Arturo Bonometti, Massimo Magagnoli, Rita Mazza, Marcello Rodari, Laura Giordano, Stefania Bramanti, Carmelo Carlo-Stella, Armando Santoro

Blood (2024) 144 (Supplement 1): 1681.

https://doi.org/10.1182/blood-2024-203287

Published: 2024

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Blood (2023) 142 (Supplement 1): 3017.

https://doi.org/10.1182/blood-2023-173677

Published: 2023

Journal Articles

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Blood (2023) 142 (Supplement 1): 433.

https://doi.org/10.1182/blood-2023-173951

Published: 2023

Journal Articles

Roginolisib a Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) in Patients with Refractory/Relapsed Follicular Lymphoma

Carmelo Carlo-Stella, Michael Lahn, Tracey Hammett, Paramjit Kaur, Rebeca Zorrilla, Giusy Di Conza, Lars van der Veen, Catherine Pickering, Armando Santoro

Blood (2023) 142 (Supplement 1): 6114.

https://doi.org/10.1182/blood-2023-180671

Published: 2023

Journal Articles

Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody

Iryna Dekhtiarenko, Iva Lelios, Wolfgang Jacob, Meike Schneider, Martin Weisser, Carmelo Carlo-Stella, Salomon Manier, Simon J. Harrison, Rakesh Popat, Anna Caroline Hasselbalch Riley, Ann-Marie E. Bröske

Blood (2023) 142 (Supplement 1): 1948.

https://doi.org/10.1182/blood-2023-177669

Published: 2023

Journal Articles

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lorenzo Falchi, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquin Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppä, Aurelien Berthier, Martine Kallemeijn, James Relf, Saibah Chohan, Linda Lundberg, Martin Hutchings

Blood (2023) 142 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2023-173949

Published: 2023

Journal Articles

Improving Therapeutic Adherence in Oncohematological Patients with a Software Application: The Margherita Study

Serena Camilla Dalto, Antonella Romanelli, Martina Violati, Martina Zucca, Fiammetta Ferrandi, Carlotta Galeone, Carmelo Carlo-Stella, Mauro Moroni, Vittorio Montefusco

Blood (2023) 142 (Supplement 1): 5072.

https://doi.org/10.1182/blood-2023-180245

Published: 2023

Journal Articles

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Armando Santoro, Alison J. Moskowitz, Silvia Ferrari, Carmelo Carlo-Stella, Julie Lisano, Stephen Francis, Rachael Wen, Alev Akyol, Kerry J. Savage

Blood (2023) 141 (22): 2780–2783.

https://doi.org/10.1182/blood.2022017951

Published: 2023

Includes: Supplemental data

Journal Articles

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

Antonino Carbone, Annunziata Gloghini, Carmelo Carlo-Stella

Blood (2023) 141 (18): 2187–2193.

https://doi.org/10.1182/blood.2022016590

Published: 2023

Journal Articles

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Blood (2022) 140 (Supplement 1): 3673–3677.

https://doi.org/10.1182/blood-2022-157583

Published: 2022

NARROW

Evolution of the Evidence for the Management of COVID-19 in Hematologic Malignancies: A Systematic Literature Review of Remdesivir

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy

Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma

Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Roginolisib a Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) in Patients with Refractory/Relapsed Follicular Lymphoma

Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Improving Therapeutic Adherence in Oncohematological Patients with a Software Application: The Margherita Study

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only